NNC0361-0041
/ Novo Nordisk
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
May 13, 2024
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=47 | Completed | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Apr 2024 | Trial primary completion date: May 2024 ➔ Aug 2023
Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
October 30, 2023
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: May 2024 ➔ Jun 2025 | Trial primary completion date: Sep 2023 ➔ May 2024
Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
June 29, 2023
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
April 20, 2023
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Jan 2024 ➔ Jun 2024 | Trial primary completion date: Jan 2024 ➔ Aug 2023
Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
November 03, 2022
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Dec 2024 ➔ Jan 2024
Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
April 15, 2022
TOPPLE T1D: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Jul 2022 ➔ Dec 2024 | Trial primary completion date: Jul 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
January 22, 2021
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1; N=48; Recruiting; Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2022 ➔ Jul 2022; Trial primary completion date: Dec 2021 ➔ Jul 2022
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
February 21, 2020
TN27: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
(clinicaltrials.gov)
- P1; N=48; Not yet recruiting; Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
New P1 trial
1 to 8
Of
8
Go to page
1